Ryoo Byung-Hwan – CEO, Yungjin – South Korea
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Yungjin Pharm. Co., Ltd was established in 1952, has been playing a major role as a forerunner in the Korean pharmaceutical industry for half a century. With the corporate mission of “To relieve the suffering of mankind from diseases with our innovative, effective and safe pharmaceutical products”, Yungjin has contributed to human health not only within Korea, but also through global expansion. As a result, Yungjin has received a total of 25 awards including the President’s Award for Superior Product Development, the Prime Minister’s Award, several Industry Awards, and many more. These accomplishments demonstrate Yungjin’s sustainability and commitment to the development of innovative products and business excellence in both overseas and domestic segments.
Contact Details:
451-20, Cheonho-dong,
Gangdong-gu,
Seoul, Korea
Tel : 82 2 2041 8200
Fax : 82 2 4630 9544
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Julien Samson, vice president and general manager of GSK Korea explains how GSK’s new global strategy is being delivered within the Korean affiliate. Mr Samson explains the focus areas for…
As the 3rd largest pharma region in Asia, Korea’s booming pharma industry owes much to its mass of family-run conglomerates known as Chaebol. It comes as no surprise to find tech…
Shingyu Bae, CEO of MDimune, explains how the company’s new exosome drug delivery system increases efficacy and reduces toxicity compared with other oncology products. He also discusses the potential and…
Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals…
Kyung Kook Lee, chairman of KMDIA, explains the association’s role in working with the medical devices industry to boost both the local market and to raise Korea’s profile as a…
Jung Hyun Yun lifts the lid on Biosolution’s new stem cell technology that could revolutionize the treatment of cartilage-related ailments, such as osteoarthritis. He also discusses the plans for global…
Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and keep under control. Korea is one of the…
Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market,…
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced…
Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for…
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
Yong-Ik Kim, president of Korea’s National Health Insurance Service (NHIS), provides an insight into the implementation of the upcoming MoonCare reforms, the government’s strategy to ensure the expansion of coverage…
See our Cookie Privacy Policy Here
